1. Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species. (4th February 2022) Authors: Hardwick, Rhiannon N; Brassil, Patrick; Badagnani, Ilaria; Perkins, Kimberly; Obedencio, Glenmar P; Kim, Andrea S; Conner, Michael W; Bourdet, David L; Harstad, Eric B Journal: Toxicological sciences Issue: Volume 186:Number 2(2022) Page Start: 323 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗